Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.006
Neutral
RSI(14)
50.577
Neutral
STOCH(KDJ)(9,3,3)
66.745
Buy
ATR(14)
0.294
High Vlolatility
CCI(14)
71.751
Neutral
Williams %R
23.226
Buy
TRIX(12,20)
-0.297
Sell
StochRSI(14)
100.000
Buy
Search
Cingulate Inc
CINGAdd to Watchlist
4.790USD
+0.030+0.63%
Close 07-31 16:00（ET）Quotes delayed by 15 min
57.04MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.63%
5 Days
+3.23%
1 Month
-12.43%
6 Months
-16.55%
Year to Date
+10.37%
1 Year
-7.53%
Key Figures
4.810Open
4.840High
60.63KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.51%Turnover Ratio
4.760Prev. Close
4.635Low
166.96KTurnover
LossP/E Static
3.02P/B
0.00%Div Yield TTM
-128.82%ROA
11.89052wk High
0.43Volume Ratio
-15.55MNet Profit
11.91MShares
-4.3368EPS TTM
-0.84Beta
-225.11%ROE
3.20052wk Low
4.30%Amplitude
--Gross Margin
57.04MMarket Cap
-1.87Reward/Risk
5.44%Risk Rate
Cingulate Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
4
analysts
Buy
Current Rating
23.000
Target Price
+408.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cingulate Inc
CING
4
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
4.625
Buy
MA10
4.678
Buy
MA20
4.741
Buy
MA50
4.758
Buy
MA100
5.430
Sell
MA200
5.090
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cingulate Inc Info
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Ticker SymbolCING
CompanyCingulate Inc
CEOCallahan (Jennifer L)
Websitehttps://www.cingulate.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Cingulate Inc (CING)?
The current price of Cingulate Inc (CING) is 4.75.
What is the symbol of Cingulate Inc?
The ticker symbol of Cingulate Inc is CING.
What is the 52-week high of Cingulate Inc?
The 52-week high of Cingulate Inc is 11.89.
What is the 52-week low of Cingulate Inc?
The 52-week low of Cingulate Inc is 3.20.
What is the market capitalization of Cingulate Inc?
The market capitalization of Cingulate Inc is 34.44M.
Is Cingulate Inc (CING) currently rated as Buy, Hold, or Sell?
According to analysts, Cingulate Inc (CING) has an overall rating of Buy, with a price target of 23.00.
What is the Earnings Per Share (EPS TTM) of Cingulate Inc (CING)?
The Earnings Per Share (EPS TTM) of Cingulate Inc (CING) is -4.44.